RTP Mobile Logo
Submitted by web@researchtop... on Mon, 04/02/2018 - 10:00
LCU118

Interview with Matthew D Hellmann, MD

Track 1: Thyroid dysfunction during checkpoint blockade in non-small cell lung cancer (NSCLC)
Track 2: Pathophysiology of thyroid dysfunction associated with immune checkpoint inhibitors
Track 3: Endocrinopathies induced by immune checkpoint inhibitors
Track 4: Risk of pneumonitis with anti-PD-1/PD-L1 antibodies
Track 5: Safety of re-treatment with immunotherapy after immune-related toxicity in patients treated with checkpoint inhibitors
Track 6: Duration of immune checkpoint inhibitor therapy
Track 7: Checkpoint inhibitors in patients with preexisting autoimmune disorders
Track 8: Clinical utility of immune checkpoint inhibitors in patients with solid organ transplant, HIV or hepatitis B or C
Track 9: Response to immune checkpoint inhibitors in patients with targetable driver mutations
Track 10: Efficacy and tolerability of neoadjuvant nivolumab in early-stage, resectable NSCLC
Track 11: Case: A 75-year-old woman with Stage II large cell neuroendocrine tumor of the lung experiences a complete pathologic response to neoadjuvant nivolumab on a clinical trial
Track 12: PD-L1 expression and prediction of response to immune checkpoint inhibitors
Track 13: Correlation between tumor mutation burden and response to immunotherapy
Track 14: PACIFIC: Results of a Phase III trial of durvalumab after chemoradiation therapy for Stage III NSCLC
Track 15: Incidence and management of chemoradiation-associated pneumonitis; lack of a significant increase in pneumonitis with durvalumab versus placebo on the PACIFIC trial
Track 16: Potential explanations for the synergy of durvalumab and chemoradiation therapy on the PACIFIC trial
Track 17: Integration of durvalumab into the therapeutic algorithm for Stage III NSCLC
Track 18: Ongoing trials of neoadjuvant anti-PD-1/PD-L1 antibodies in Stage III lung cancer
Track 19: Results of CheckMate 012: Activity and tolerability of nivolumab with ipilimumab as first-line therapy for advanced NSCLC
Track 20: Nivolumab/ipilimumab for advanced small cell lung cancer
Track 21: MYSTIC trial: Lack of progression-free survival benefit with durvalumab/tremelimumab versus platinum-based chemotherapy for previously untreated metastatic NSCLC
Track 22: FLAURA study results: Improvement in progression-free survival and tolerability with osimertinib versus erlotinib or gefitinib as first-line therapy for EGFR-mutated advanced NSCLC
Track 23: Ongoing trials evaluating immune checkpoint inhibitor-based regimens in NSCLC
Track 24: Biological and pharmacological differences among checkpoint inhibitors
Track 25: Updated results of the Phase II IFCT-1501 MAPS2 trial of second- or third-line nivolumab in malignant pleural mesothelioma
Track 26: CheckMate 026: Results from a Phase III trial of nivolumab versus chemotherapy as first-line therapy for patients with Stage IV or recurrent PD-L1-positive NSCLC

Interview with Lecia V Sequist, MD, MPH

Track 1: Case: A 75-year-old woman and former smoker with recurrent squamous cell carcinoma (SCC) of the lung is found to harbor a MET exon 14 skipping mutation and receives crizotinib
Track 2: Perspective on the PACIFIC trial results
Track 3: Activity of gemcitabine monotherapy in SCC of the lung
Track 4: Incidence of MET exon 14 skipping mutations in SCC of the lung; response to crizotinib
Track 5: Acquired resistance to crizotinib in patients with NSCLC and MET exon 14 skipping mutations
Track 6: Case: A 50-year-old woman and never smoker with advanced adenocarcinoma of the lung and an EGFR L858R mutation
Track 7: Efficacy and tolerability of afatinib for metastatic EGFR L858R mutation-positive adenocarcinoma of the lung
Track 8: Activity of osimertinib in patients with leptomeningeal disease from EGFR-mutated advanced NSCLC
Track 9: FLAURA study results: Osimertinib versus erlotinib or gefitinib as first-line therapy for EGFR-mutated advanced NSCLC
Track 10: Clinical implications of the FLAURA trial results on T790M resistance mutation testing
Track 11: Efficacy of immune checkpoint inhibitors versus chemotherapy in patients with EGFR wild-type versus mutated NSCLC
Track 12: Case: A 68-year-old woman and moderate smoker with newly diagnosed metastatic adenocarcinoma of the lung, no targetable mutations and a high PD-L1 tumor proportion score (TPS)
Track 13: Pseudoprogression in patients receiving immune checkpoint inhibitors
Track 14: Re-treatment with immunotherapy after immune-related toxicity in patients who receive anti-PD-1 antibodies
Track 15: Case: A 57-year-old man and former smoker with symptomatic KRAS mutation-positive adenocarcinoma of the lung and a high PD-L1 TPS
Track 16: Perspective on the clinical utility of ramucirumab or bevacizumab in advanced NSCLC
Track 17: Case: A 63-year-old woman with heavily pretreated EGFR L858R mutation-positive adenocarcinoma of the lung who expresses interest in nivolumab/ipilimumab
 
FACULTY
 
Matthew D Hellmann, MD
Medical Oncologist
Memorial Sloan Kettering
Cancer Center
New York, New York
 
Lecia V Sequist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Center for Thoracic Cancers
Massachusetts General Hospital
Cancer Center
Boston, Massachusetts
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida